RAPID-An open-label randomized, multicenter phase IIIb study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia/schizoaffective disorder (rapid versus conventional titration)

Trial Profile

RAPID-An open-label randomized, multicenter phase IIIb study to evaluate the efficacy and tolerability of quetiapine IR (immediate release), over 14 days, in acute schizophrenia/schizoaffective disorder (rapid versus conventional titration)

Suspended
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms RAPID
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Sep 2010 Status changed from discontinued to suspended as reported by United Kingdom Clinical Research Network.
    • 22 Dec 2008 New source identified and integrated (United Kingdom Clinical Research Network record)
    • 10 Nov 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top